Skip to main content

Kenvue Inc.

corporate_fare Company Profile

Kenvue Inc.

KVUE·NYSE·Industrial Applications And Services·CIK 0001944048

Kenvue is a global leader in consumer health, operating at the intersection of healthcare and consumer goods. The company is the world's largest pure-play consumer health company by revenue, with $15.1 billion in Net sales in the fiscal year 2025. Kenvue combines science, consumer insights, and a digital strategy to help consumers live healthier lives. Its portfolio of brands, built on over a century of heritage, includes Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena®, Nicorette®, Tylenol®, and Zyrtec®. These brands are backed by science and recommended by healthcare professionals. Kenvue's product portfolio is divided into three segments: Self Care, Skin Health and Beauty, and Essential Health products. The company markets its products across more than 165 countries worldwide, reaching consumers in North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). Kenvue's global scale and broad brand portfolio are supported by its capabilities and digital strategy, enabling it to respond to trends in its categories and geographic markets. The marketing organization uses precision marketing, e-commerce, and digital capabilities to develop consumer insights and enhance brand relevance. The research and development organization combines these insights with scientific expertise and engagement with healthcare professionals to drive innovative new products and solutions centered on consumer health.

Kenvue Inc. (NYSE:KVUE) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 32 items for KVUE at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Kenvue CFO Amit Banati to Depart Amidst Pending Kimberly-Clark Merger
  • Kenvue Stockholders Overwhelmingly Approve Kimberly-Clark Merger Agreement
  • Kimberly-Clark Reports Strong Shareholder Support for Kenvue Merger Ahead of Vote, Reaffirms $2.1B Synergies
  • Kenvue Amends Merger Proxy Statement Following Multiple Shareholder Lawsuits
  • Kenvue Amends Merger Proxy Statement Amid Shareholder Lawsuits Challenging Kimberly-Clark Deal Disclosures

Financial Snapshot

Fiscal year ended December 28, 2025
Revenue
$15.12B
Net Income
$1.47B
Diluted EPS
$0.76
Op. Cash Flow
$2.2B
Free Cash Flow
$1.72B
Gross Profit
$8.79B
Operating Income
$2.41B
Cash & Equivalents
$1.06B
Total Debt
$750M
Debt / Equity
0.07×
Net Margin
9.7%
Shares Outstanding
1.92B sh
Source: 10-K · filed 2026-02-20 · accession 0001944048-26-000030
$19.31
Market cap
$37.09B
Volume
66.6M (3.3× avg)
3-mo avg 20.1M
Last traded · 2026-11-02

show_chartPrice Chart

Loading chart...

feed KVUE - Filings & News (Page 2)

KVUE
Feb 12, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.54
Real-time Price: $19.31 info
Change: +$0.770 (+4%) info
Market Cap: $37.09B info
KVUE
Jan 29, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.22
Real-time Price: $19.31 info
Change: +$2.09 (+12%) info
Market Cap: $37.09B info
KVUE
Jan 27, 2026, 5:21 PM EST
Filing Type: 425
Importance Score:
9
Price at Filing: $17.50
Real-time Price: $19.31 info
Change: +$1.81 (+10%) info
Market Cap: $37.09B info
KVUE
Jan 16, 2026, 5:29 PM EST
Filing Type: 425
Importance Score:
8
Price at Filing: $17.16
Real-time Price: $19.31 info
Change: +$2.15 (+13%) info
Market Cap: $37.09B info
KVUE
Jan 16, 2026, 5:28 PM EST
Filing Type: 425
Importance Score:
8
Price at Filing: $17.17
Real-time Price: $19.31 info
Change: +$2.14 (+12%) info
Market Cap: $37.09B info
KVUE
Jan 16, 2026, 5:27 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.16
Real-time Price: $19.31 info
Change: +$2.15 (+13%) info
Market Cap: $37.09B info
KVUE
Jan 16, 2026, 5:23 PM EST
Filing Type: 425
Importance Score:
7
Price at Filing: $17.17
Real-time Price: $19.31 info
Change: +$2.14 (+12%) info
Market Cap: $37.09B info
KVUE
Jan 13, 2026, 5:20 PM EST
Filing Type: 425
Importance Score:
9
Price at Filing: $17.01
Real-time Price: $19.31 info
Change: +$2.30 (+14%) info
Market Cap: $37.09B info
KVUE
Jan 13, 2026, 5:00 PM EST
Filing Type: 425
Importance Score:
10
Price at Filing: $17.01
Real-time Price: $19.31 info
Change: +$2.30 (+14%) info
Market Cap: $37.09B info
KVUE
Jan 08, 2026, 5:05 PM EST
Filing Type: 425
Importance Score:
9
Price at Filing: $16.99
Real-time Price: $19.31 info
Change: +$2.32 (+14%) info
Market Cap: $37.09B info
KVUE
Jan 08, 2026, 4:30 PM EST
Filing Type: 425
Importance Score:
9
Price at Filing: $16.99
Real-time Price: $19.31 info
Change: +$2.32 (+14%) info
Market Cap: $37.09B info
KVUE
Jan 07, 2026, 5:15 PM EST
Filing Type: 425
Importance Score:
8
Price at Filing: $16.69
Real-time Price: $19.31 info
Change: +$2.62 (+16%) info
Market Cap: $37.09B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets